Service d'Hépato-Gastro-Entérologie, Assistance Publique - Hôpitaux de Marseille (AP-HM), Service d'Hépato-Gastro-Entérologie, Centre Hospitalo-Universitaire Timone, Marseille, France.
Curr Opin Infect Dis. 2019 Oct;32(5):475-481. doi: 10.1097/QCO.0000000000000590.
Hepatitis E virus (HEV) has gained increased global recognition in recent years, particularly in developed countries. We summarized here a selection of the literature published since the 1st of June, 2017.
Longitudinal studies are increasingly conducted in Europe, to determine trends in HEV prevalence. The spectrum of mammals infected with HEV and potentially capable to transmit it to humans has widened. New virological data on HEV repCon and pathogenicity have been reported and clinical features of HEV infections have been precised or newly described. Finally, there are some new data on the therapeutic management of HEV infections in various clinical settings.
HEV emergence in developed countries appears to be based on improved diagnosis tools and increased awareness of clinicians that HEV transmission is essentially autochthonous and is a possible cause of life-threatening acute hepatitis, chronic hepatitis, cirrhosis, and extra-hepatic symptoms. In addition, the distribution of HEV strains evolves. Ribavirin remains to date the only specific treatment recommended for HEV infection, being efficient in the majority but not in all cases.
近年来，戊型肝炎病毒（HEV）在全球范围内得到了更多的关注，尤其是在发达国家。我们总结了自 2017 年 6 月 1 日以来发表的部分文献。
在欧洲，越来越多的进行了纵向研究，以确定 HEV 流行率的趋势。感染 HEV 并可能将其传播给人类的哺乳动物范围已经扩大。有关 HEV repCon 和致病性的新病毒学数据已经被报道，HEV 感染的临床特征已经被明确或新描述。最后，在各种临床情况下，HEV 感染的治疗管理方面也有一些新的数据。
发达国家的 HEV 出现似乎是基于改进的诊断工具和临床医生对 HEV 传播主要为内源性以及可能是危及生命的急性肝炎、慢性肝炎、肝硬化和肝外症状的潜在原因的认识提高。此外，HEV 株的分布也在演变。利巴韦林仍然是目前推荐的唯一针对 HEV 感染的特异性治疗方法，在大多数情况下有效，但并非所有情况下都有效。
